<p>Gene therapy seeks to target the root causes of diseases, particularly those related to genetic alterations. This approach involves utilizing genetic material to treat or prevent illnesses. The delivered genetic material, which can be either DNA or RNA, provides instructions that modify how a protein&mdash;or a group of proteins&mdash;is produced within the cell.&nbsp;</p>
<p>For certain conditions, this may involve adjusting the production levels of essential proteins that are either overproduced, underproduced, or incorrectly produced. In the field of ophthalmology, gene therapy is being explored for a variety of conditions, including dry age-related macular degeneration, wet age-related macular degeneration, Stargardt disease, retinitis pigmentosa, Leber's Congenital Amaurosis (LCA), and others.</p>
<p><strong>Gene Therapy in Ophthalmology Epidemiological Segmentation</strong></p>
<p>The Epidemiological Segmentation of Gene Therapy in Ophthalmology in 7MM from 2020 to 2034 is segmented as:-</p>
<ul>
<li>Total Diagnosed Prevalent Cases of Selected Indications for Gene Therapies in Ophthalmology in the 7MM</li>
<li>Indication-wise Eligible Cases in the 7MM</li>
<li>Indication-wise Treated Cases in the 7MM</li>
</ul>
<h2><strong>Gene Therapy in Ophthalmology Epidemiology</strong></h2>
<ul>
<li>The total diagnosed prevalent cases of Gene Therapy in Ophthalmology in the 7MM was found to be 9.2 million in 2023.</li>
<li>The diagnosed prevalent population of Gene Therapy in Ophthalmology in the United States, was found to be 112K in 2023.</li>
</ul>
<h2><span style="text-decoration: underline; color: #000000;"><strong><a style="color: #000000; text-decoration: underline;" href="https://www.delveinsight.com/report-store/gene-therapy-in-ophthalmology-market">Gene Therapy in Ophthalmology Market</a></strong></span></h2>
<p>The market size of gene therapy in ophthalmology at 7MM was USD 35 million in 2020.</p>
<p><strong>Gene Therapy in Ophthalmology Market Drivers</strong></p>
<ul>
<li>Innovative payment plans for one-time gene therapies.</li>
<li>Significant advancements in gene therapy for treating genetic eye disorders.</li>
</ul>
<p><strong>Gene Therapy in Ophthalmology Market Barriers</strong></p>
<ul>
<li>Challenges in delivering therapies to delicate eye tissues.</li>
<li>Reimbursement difficulties leading to drug withdrawals in Europe.</li>
</ul>
<h2><strong>Gene Therapy in Ophthalmology Emerging Drugs</strong></h2>
<p>The emerging drugs in the Gene Therapy Ophthalmology market are</p>
<ul>
<li>Botaretigene sparoparvovec</li>
<li>AGTC-501</li>
<li>MCO-010</li>
<li>GS030</li>
<li>4D 125</li>
<li>And many others.</li>
</ul>
<h2><strong>Gene Therapy in Ophthalmology Players</strong></h2>
<p>The key players in the Gene Therapy in Ophthalmology market are</p>
<ul>
<li>Johnson &amp; Johnson Innovative Medicine /MeiraGTx</li>
<li>Beacon Therapeutics</li>
<li>Nanoscope Therapeutics</li>
<li>Gensight Biologics</li>
<li>4D Molecular Therapeutics</li>
<li>And many others.</li>
</ul>

Gene Therapy in Ophthalmology Market

Gene Therapy in Ophthalmology Infographic

Gene Therapy in Ophthalmology Market Infographic

Gene Therapy in Ophthalmology Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.